Anna C. Pavlick

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow, Jason Chesney, Anna C. Pavlick et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text

Life Sciences, Immunology, Oncology +17

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +16

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas, Igor Puzanov, Reinhard Dummer et al. · The Lancet Oncology · 2015 · 1.6K citations · Full text

Medicine, Clinical Sciences, Oncology +15

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

Medicine, Neurology, Oncology +14

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

F. Stephen Hodi, Jason Chesney, Anna C. Pavlick et al. · The Lancet Oncology · 2016 · 980 citations

Medicine, Immunology, Oncology +17